FibroBiologics, Inc. (FBLG)
- Previous Close
10.31 - Open
9.20 - Bid 9.54 x 100
- Ask 9.40 x 100
- Day's Range
8.71 - 10.55 - 52 Week Range
6.42 - 46.00 - Volume
278,612 - Avg. Volume
127,977 - Market Cap (intraday)
313.776M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.
www.fibrobiologics.comRecent News: FBLG
Performance Overview: FBLG
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FBLG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FBLG
Valuation Measures
Market Cap
313.78M
Enterprise Value
307.73M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
300.03
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-49.88%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-22.53M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
8.16M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
7.67M
Company Insights: FBLG
FBLG does not have Company Insights